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Aims Increased sympathetic activation and reduced parasympathetic tone are important pathophysiological contributors
to the progression of heart failure, and are associated with poor outcome in patients. The aim of this study is to
determine if vagal nerve stimulation (VNS) is a promising approach to modulate autonomic function and slow cardiac
remodelling and the progression of heart failure.
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Methods The NECTAR-HF (NEural Cardiac TherApy foR Heart Failure) trial is designed to evaluate whether the Boston
Scientific VNS device is safe and may attenuate cardiac remodelling, improve cardiac function and increase exercise
capacity, in symptomatic heart failure patients (New York Heart Association Class II–III) with left ventricular systolic
dysfunction (ejection fraction ≤35%) and receiving optimal medical therapy. Patients will be randomized in a 2:1 ratio
to receive standard optimal medical treatment plus VNS system in an active mode vs. optimal medical treatment plus
VNS system in an inactive mode, for a 6 month period. After the 6 month control period, inactive VNS systems will be
activated and all patients will receive VNS. The study is powered to detect differences in the primary efficacy endpoint
of change in left ventricular end systolic diameter. Secondary endpoints include ejection fraction, left ventricular
volumes, quality of life scores, functional capacity, and changes in biomarkers.
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Conclusion This Phase II, randomized clinical trial conducted with vagal stimulation for heart failure will provide important new
information on the potential of this novel and promising technique.
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Introduction
Congestive heart failure is a syndrome that affects nearly 23 mil-
lion people worldwide, with approximately 2 million new patients
diagnosed annually.1 Despite substantial advances over the past
two decades in pharmacological therapy and device therapy,2
heart failure remains one of the leading causes of morbidity and











.. mortality. Increased sympathetic activation and reduced parasym-
pathetic tone (as reflected by reduced baroreflex sensitivity and/or
decreased heart rate variability) are important pathophysiological
contributors to the progression of heart failure (HF) irrespective
of aetiology, and are associated with poor outcome in patients
with congestive heart failure.3,4 Reducing sympathetic drive with
anti-adrenergic pharmacological agents has shown to be beneficial.
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Augmenting the parasympathetic tone via direct vagal stimulation
was recently assessed in a non-randomized observational study
of 32 HF patients with left ventricular (LV) systolic dysfunction
suggesting that vagal stimulation was safe and might favourably influ-
ence LV remodelling.5,6
The NECTAR-HF (NEural Cardiac TherApy foR Heart Failure)
trial is designed to evaluate whether right vagal nerve stimulation
is safe and might attenuate cardiac remodelling, improve cardiac
function, and increase exercise capacity in symptomatic HF patients




(i) Age 18 years or above, and of legal age to give informed
consent specific to national laws.
(ii) Willing and capable of providing informed consent.
(iii) Capable of participating in all testing associated with this
clinical investigation.
(iv) Stable symptomatic HF New York Heart Association (NYHA)
class III, amended to include NYHA classes II and III.
(v) Left ventricular (LV) ejection fraction <35% (equal or smaller
than 35 %) documented in patient file within the past
6 months.
(vi) Left ventricular end diastolic diameter (LVEDD) of 5.5 cm or
greater documented in patient file within the past 6 months.
(vii) Prescribed to optimal pharmacological therapy according to
current local or international guidelines for treatment of
acute and chronic HF at the time of enrolment, unless
contraindicated or not-tolerated, and on a stable dose (e.g.
recommended no greater than a 50% increase or decrease in
dosage, amended to ‘no greater than a 100% increase or 50%
decrease in dosage’) for at least 30 days before enrolment.
Abbreviated exclusion criteria:
(i) Cardiac resynchronization therapy (CRT), subsequently
amended to exclude patients with CRT for less than 1 year
before enrolment (the total number of CRT patients will not
exceed 30).
(ii) Patients who have been hospitalized for HF and who required
the use of HF IV therapy within 30 days before enrolment.
(iii) Patients with unstable angina, myocardial infarction, percuta-
neous transluminal coronary angioplasty (PTCA), coronary
artery bypass graft, cerebral vascular accident, or transient
ischaemic attack within previous 3 months (90 days) before
enrolment.
(iv) Patients whose primary cause of HF is mitral or aortic valve
disease, classified as severe valve disease.
(v) Patients with persistent or permanent atrial fibrillation (AF)
(according to the current local or international guidelines for




















































































Figure 1 The NCT lead is for investigational use only.
within 180 days before enrolment, amended to within 90 days
before enrolment.
(vi) Pacemaker-indicated patients.
(vii) Patients actively treated, amended to patients who have
started treatment within the previous 6 months before enrol-
ment, for sleep apnoea or sleep-disordered breathing with
therapies to maintain airway patency [e.g. continuous posi-
tive airway pressure (CPAP), b-iphasic positive airway pressure
(BiPAP), automatic positive airway pressure (APAP)] with or
without oxygen supplementation.
(viii) Patients on or indicated for renal dialysis.
(ix) Insulin-dependent diabetic patients, amended to Type 1 dia-
betic patients and Type 2 diabetic patients that have been
treated with insulin for more than 5 years before enrolment.
(x) Patients implanted with any active implantable medical device
other than a left-sided single or dual chamber implantable
cardioverter defibrillator (ICD) with bipolar sensing, amended
to add other than a left-sided CRT device with each sensing
channel programmed to either bipolar sensing or no sensing.
All enrolled CRT patients must have had CRT for at least 1 year
before enrolment.
Boston Scientific vagal nerve stimulation
(VNS) system
The Boston Scientific VNS system is investigational. It consists of
the investigational vagal cuff lead (NCT Lead; Boston Scientific
Corporation, St. Paul, MN, USA) and of an implantable pulse
generator (PrecisionTM; Boston Scientific Corporation). The NCT
lead (see Figure 1) is a single lead with a bipolar, helical cuff, with an
active anode and cathode, as well as a non-active strain relief cuff.
Investigational therapy
The investigational vagal cuff lead is implanted in all patients by
exposing approximately 4–6 cm of the vagus nerve on the right
side of the neck. The lead is then tunnelled over the clavicle and
connected to a pulse generator (Figure 2). The procedure can be
performed under general or local anaesthesia by an appropriately
trained and experienced vascular/cardiovascular surgeon or neu-
rosurgeon. Although the recommendation is to use general anaes-
thesia, the surgical team may decide to use local anaesthesia if there
is concern about patient safety. Based upon the clinical experience
of vagal nerve implants to treat epilepsy, the procedure will take
90 minutes or less to implant in most cases.
© 2014 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 2 The NECTAR-HF (NEural Cardiac TherApy foR
Heart Failure) implant location. The lead is placed around the
cervical vagus nerve and then tunnelled across the clavicle and
connected to the pulse generator, which is located in a pectoral
pocket.
Stimulation testing and therapy titration
Once implanted, the system is evaluated by checking the impedance
of both electrodes, and then by performing brief stimulation to
look for one or more of the following as evidence of proper sys-
tem functioning and implant location: activation of the larynx, an
acute heart rate reduction of greater than 5 beats, or a respiratory
response (breath reflex). For patients assigned to the active treat-
ment group, therapy is delivered at 20 Hz for 10 s out of every
minute. Titration is performed in all patients, by increasing the
current amplitude (mA) slowly to allow for accommodation of
anticipated side-effects, such as hoarse voice, a tickling sensation
in the throat, brief cough, or muscle fasciculation that may occur
at higher stimulation. The goal is to titrate patients to the maxi-
mum tolerable dose, not to exceed 8 mA during the implant and
not exceeding 4 mA chronically.
Study procedures
Figure 3 shows the flow of the study visits.
Screening and baseline evaluation
Following confirmation of inclusion/exclusion criteria and patient
consent, pre-implant screening is performed to confirm the eligibil-
ity criteria, including left ventricular ejection fraction (LVEF) ≤35%
and LVEDD >5.5 cm. All eligible patients are scheduled for implan-
tation of the Boston Scientific VNS system. At 14± 5 days after
implant patients return for the collection of baseline data (Figure 3).
Medical assessment, NYHA class status assessment, echocardio-



















































































.. investigators blinded to treatment assignment. Data are uploaded
electronically to an internet-based electronic data capture system
and sent to the core laboratories for blinded analysis.
Randomization
At the end of the baseline visit, patients are randomized 2:1 to
therapy or control in permuted blocks within each centre, stratified
by clinical site. Using randomization blocks conceals treatment
allocation. The randomization is performed using an electronic
database at the time of the baseline visit.
Blinding
Following randomization, all patients undergo the first of four titra-
tions (including the baseline visit) during a 30 day window (Figure 3).
Although every attempt is made to blind treatment assignment,
many patients feel the stimulation as a slight tickling/vibration in the
neck. Thus, complete blinding is not feasible. However, assessment
of all endpoint-related data are performed by blinded clinicians,
protecting data integrity from treatment assignment bias. At the
6 month follow-up, patients that were randomized to the control
group will be crossed over to begin receiving therapy. They will
also receive an additional three titrations during the first 30 days
following the 6 month visit. This ensures optimal programming of
the VNS system.
Follow-up
There are two phases to the study. The primary study phase con-
sists of approximately 19 months of follow-up visits after implant
for each patient. These 19 months include the 30 days needed for
titration after baseline and the following 18 months of follow-up
time with regularly reoccurring visits. Following the fourth titra-
tion after implant, patients return to the clinic at 3 months for
a device check and therapy titration, and then again at 6 months
for collection of all efficacy-related endpoint data (Figure 3). After
this patients return to the clinic every 3 months during a 12 month
period of safety follow-up. As patients complete the primary study
phase, they enter the extended follow-up phase and continue to
receive therapy up to the end of the trial, or indefinitely if is not
stopped prematurely for safety concerns. Once all patients com-
plete the primary study phase, a data safety monitoring committee
(DSMC) will convene and make a recommendation on whether to
continue with active therapy or to terminate the study and deacti-
vate devices.
Efficacy endpoint
Preclinical evidence indicated that a 10% reduction in left-
ventricular end systolic diameter (LVESD) is achievable with
vagal stimulation.7 Thus, we used a change of 6 mm in LVESD
from baseline to 6 months for statistical calculations. With a 2:1
randomization, a power of 80% at minimum, and accounting for
patient and data attrition of up to 40%, the required number
of patients to receive the Boston Scientific VNS system has
© 2014 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 3 Study flow chart and data collection. CPET, cardiopulmonary exercise test; HF, heart failure; LVEDD, left ventricular end diastolic
diameter; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association; QOL, quality of life.
been estimated to be 96 patients. To assess the primary efficacy
endpoint of LVESD, analysis will be carried out on a modified
intention-to-treat basis as specified in the NECTAR-HF protocol.





.. sets will be analysed. However, a strict intention-to-treat analysis
will also be performed, including all patients, regardless of whether
they have a complete echo data set or not. For all other efficacy
endpoints patients must have a complete data set for the variable
© 2014 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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being considered for inclusion in the analysis [e.g. peak oxygen
consumption (VO2), quality of life (QOL)]. To test the hypothesis
for the primary endpoint a general linear model will be used,
including baseline LVESD as a covariate in the model.
Safety endpoint
At the end of the primary study phase (approximately 19 months
after baseline, and 18 months of follow-up), a safety endpoint of
all-cause mortality will be evaluated. Survival will be estimated
using Kaplan–Meier methodology and will be compared with an
objective performance criterion (OPC) of 65%, derived from the
75% survival at 18 months observed in the COMPANION8 study
control group of NYHA class III patients factoring in a clini-
cally meaningful delta of −10%. Patients will be entered into the
Kaplan–Meier risk set at the protocol-defined time of therapy acti-
vation. A 95% one-sided lower confidence limit will be calculated
for the survival estimate and compared with the OPC of 65%. If
the lower limit is at least as large as the OPC, it will be concluded
that NECTAR-HF has 95% confidence that survival is at least 65%.
Echocardiography
A cardiac imaging core laboratory (CICL) is used to perform
echocardiography analysis for endpoint-related data. The echocar-
diography examination should be performed before any exercise
test, or no sooner than within 2 h of finishing the exercise test. The
parasternal long and short axis, and the apical four-, five-, two-,
and three-chamber views with and without Doppler assessment
are required. An electronic copy [e.g. digital imagining and com-
munications in medicine (DICOM)] of the pre-implant baseline
echocardiography and of subsequent follow up echocardiographies
(6, 12 and 18 month follow-up visits) is sent to the CICL within
five working days. The following echocardiographic assessments
are made by the CICL: global ventricular size and function includ-
ing LVEF, end-diastolic volume and diameter, end-systolic volume,
diameter and mass; left atrial size, including left atrial volume; mitral
regurgitation severity; and left ventricular diastolic function, includ-
ing mitral inflow Doppler and mitral annular tissue Doppler param-
eters. All measurements are made in triplicate. In patients who have
developed new atrial fibrillation during the course of the trial, echo
measurements should be repeated five times.
Cardiopulmonary exercise test (CPET)
Briefly, the testing protocol consists of an initial rest period
(minimum of 3 min) and staged exercise. The workload begins
at 25 W and increases 10 W every minute. A peak respiratory
exchange ratio of 1.1 is strongly encouraged. A minimum 5 min
recovery period follows termination of exercise. The CPET may
be conducted on either a treadmill or cycle ergometer but the
exercise modality selected for an individual patient must be the
same at all CPET examinations. Respiratory gases are analysed
using a calibrated metabolic cart capable of recording breath-
by-breath data (mixing chamber method is also acceptable). A



















































































.. oxygen consumption, peak respiratory exchange ratio, exercise
duration, and work performed. Submaximal functional capacity
will be assessed by ventilatory anaerobic threshold (VT). Before
an investigational site being authorized to enrol patients in the
NECTAR-HF study, a CPET certification needs to be completed,
assessing the site’s CPET testing capabilities, such as equipment
function and calibration, proper demonstration of a valid maximal
exercise test, and data formatting for electronic submission into
the database. In order to maintain data quality standards, all sites
will be required to recertify if a 6 month period lapses without a
CPET of a study patient.
Quality of life assessment
Patients are asked to complete two QOL questionnaires at visits as
described in Figure 3. The Medical Outcomes Study Short-Form 36-
Item Health Survey (SF-36), which includes 36 items that measure
general, physical and mental health, and the Minnesota Living
with Heart Failure© (MLHFQ) survey questionnaire evaluating
the patient’s perception of how his/her HF and therapy affects
his/her life.
Biomarkers
To identify markers predictive of response and to better under-
stand the therapy efficacy, panels of markers will be assessed
that may include specific biomarkers associated with heart failure
[e.g. BNP, atrial natriuretic peptide (ANP), ST2, mid-regional pro-
adrenomedullin (MR-proADM), endothelins, miRNA423], inflam-
mation [e.g. tumour necrosis factor alpha (TNF𝛼), interleukin-6 (IL-
6), C-reactive protein (CRP), vascular adhesion protein-1 (VAP-1)],
apoptosis [e.g. caspase-3, Fas-ligand (Fas-L)], remodelling [e.g. col-
lagen, N-terminal propeptide of human procollagen type I (PINP),
N-terminal propeptide of Type III procollagen (PIIINP), Pyridinoline
cross-linked carboxyterminal telopeptide of type I collagen (ICTP),
matrix metalloproteinase-3 (MMP-3), matrix metalloproteinase-9
(MMP-9), Tissue inhibitor of metalloproteinase 1 (TIMP-1)], car-
diac stress (copeptin), cardiac contraction [e.g. sarcoendoplas-
mic reticulum calcium ATPase (SERCA-2), ryanodine receptor],
and neuro-hormonal activation [e.g. acetyl choline (Ach), cate-
cholamines, vasoactive intestinal peptide (VIP)].
Oversight committees
A steering committee will oversee the detail conduct of the trial
from conception to termination, interpretation of the results, and
final publication of the results. A DSMC has been appointed to
direct data analyses needed for assessing treatment effects during
the trial. Interim reports will be reviewed for evidence of adverse
events/effects and, accordingly, will advise the steering committee
and the sponsor on any possible changes required in the treatment
protocol. A clinical event committee (CEC) has been formed to
review and adjudicate reports prepared by the data coordinating
group to detect any possible safety issue and/or related deficiencies
in data collection if required. The committee is responsible to
review the data from four different types of events, including
© 2014 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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deaths, system failure, system infections, and ICD interaction.
The CEC may adjudicate other safety issues as well. A listing of
committee members can be found Appendix 1.
Discussion
The restoration/augmentation of parasympathetic tone has
recently emerged as a promising therapeutic approach to nor-
malizing autonomic imbalance and inhibiting the progression
of HF.
The first experimental study to show the potential of chronic
vagal stimulation to improve cardiac function was that of Li et al.9
Rats subjected to a large anterior myocardial infarction (MI) lead-
ing to heart failure were randomized 14 days post-MI to sham
stimulation or active vagal stimulation for 10 s every minute with
intensity adjusted to reduce heart rate by 20–30 bpm from a start-
ing value of 360 bpm. The treated rats had significantly lower LV
end-diastolic pressure and higher maximum dp/dt of left ventricular
pressure than the untreated rats. Improvement of cardiac pumping
function was accompanied by a decrease in normalized biventricu-
lar weight and, more strikingly, by a 73% decrease in mortality from
50% to 14% at 140 days.
Zhang et al.10 studied the effects of chronic vagal stimulation
delivered at a frequency of 20 Hz, a duty cycle of 14 s on and 12 s
off, and an intensity individually titrated to reduce sinus rate by
approximately 20% in a canine model of HF induced by high-rate
ventricular pacing. The dogs were subjected to 8 weeks of high-rate
ventricular pacing with concomitant vagus nerve stimulation in the
active group and no stimulation in the control group. Animals in
the vagus nerve stimulation group had significantly lower LV end
diastolic and end systolic volumes and higher LV ejection fraction.
In addition, vagal stimulation significantly attenuated the reduction
in baroreflex sensitivity induced by heart failure. These results were
obtained in the absence of any heart rate effect provided by vagal
stimulation as both groups were subjected to the same constant
ventricular pacing.
Sabbah et al.11 have developed a canine model of chronic HF
produced by multiple sequential coronary micro-embolizations
that has been used for a few studies with vagal stimulation. In
the first study, right vagus nerve stimulation synchronized to the
cardiac cycle with intensity adjusted with a feedback heart rate
control system to reduce baseline heart rate by approximately
10%, decreased LV end systolic and end diastolic volumes and
increased LVEF. In the same animal model, it was subsequently
shown that the addition of vagal stimulation to beta-blockade
increased LVEF and decreased LV end systolic volumes more
than obtained by beta-blockade alone12. Finally, vagal stimulation
with settings that did not cause any acute heart rate reduction
(being therefore lower in intensity compared with the previous
studies) decreased LV end systolic volume and increased LVEF by
a magnitude grossly similar to that achieved in the previous study
with more intense closed-loop stimulation.7 Several biomarkers of
HF were also positively affected by vagal stimulation.
Potentially beneficial effects of vagal stimulation, independent
and/or beyond heart rate decrease include a comprehensive anti-



















































































.. an increase in nitric oxide availability an anti-apoptotic effect as well
as anti-inflammatory activity.13 Tracey14 provided clear evidence of
the existence of a vagally mediated anti-inflammatory effect that
has been confirmed in several experimental studies of myocardial
ischemia and reperfusion13. Vagal stimulation has also been found
to provide a powerful anti-arrhythmic activity, particularly in the
setting of myocardial ischaemia.15,16
The clinical experience consists of one completed multi-centre,
open label, non-randomized study of 32 patients with NYHA class
II–IV and an ejection fraction of ≤35% implanted with a right
vagus nerve stimulation system and followed for up to 12 months.
There were significant improvements in the 6 min walk test, quality
of life, LVEF and LV volumes, and only two non-serious adverse
events occurred, related to the device.6 An important next step is
to extend these findings by conducting a randomized, controlled
and blinded study (i.e. endpoint evaluation is conducted by blinded
personnel). NECTAR-HF is a feasibility and proof of concept study.
It is intended to help estimate the efficacy of the Boston Scientific
VNS system on the endpoint of LV remodelling and clinical benefit.
Subsequently, this must be evaluated in an appropriate outcome
trial.
Study population
In phase II proof of concept studies, it is desirable to select a
homogeneous experimental group of patients in order to avoid
the dilution of the potential efficacy endpoint by inconsistent
effects across a heterogeneous pattern of response. Therefore,
we chose to enrol only symptomatic heart failure patients with
a dilated and dysfunctioning LV on optimal recommended therapy,
and remote from an acute event and/or CV procedure. Patients
with permanent/persistent atrial fibrillation are also excluded,
because it is unclear how VNS may affect this condition, and the
echocardiographic determination of the primary efficacy endpoint
is less accurate in these patients. Insulin-dependent Type 1 diabetes
patients and those with long lasting (>5 years) Type 2 diabetes,
as well as other conditions associated with features of autonomic
dysfunction, were other important exclusions.
Endpoints
Left ventricular end-systolic diameter has been used to evaluate
the efficacy of HF therapies in phase II studies.17 Although change
in LV dimensions is a surrogate marker for clinical benefit, it has
consistently been shown to predict the effect of HF therapies
on cardiovascular events and overall mortality.18 The minimal
follow-up period for detectable changes in cardiac remodelling
is debatable, but in recent CRT studies, a 6 month follow-up
period has been an adequate duration to prove reverse remodelling
and improvement of LV function.19,20 In NECTAR-HF all other
LV dimensions will be examined within the context of changes
in a host of secondary efficacy endpoints. The impact of vagal
stimulation on quality of life, functional capacity, and all-cause
or HF hospitalizations will also be examined to determine if
therapy provided a clinical benefit. Furthermore, changes assessed
© 2014 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
698 G.M. De Ferrari et al.
in biological markers will help to support a potential benefit of
increased vagus activity.
Control group and blinding
A randomized controlled experimental design is an essential step
in medical progress. Although sham surgery may be felt as being
a violation of regulatory and ethical principles with regard to risk
to patients,21,22 conducting studies without appropriate controls
inevitably leads to bias, incorrect interpretation and inconclusive
results. Blinding is another challenge in device trials. Stimulating the
vagus nerve is known to elicit mild side-effects in many patients, the
most prominent of which are voice alteration/throat tingling and
coughing. This introduces additional challenges in keeping patients
blinded to treatment assignment. In the NECTAR-HF study, we
employed a strategy that involves titration of both treatment and
control groups, ensuring that patients in both groups have an equal
number of visits during the 6 month randomized therapy period.
Although patients are not told of their treatment assignment, we
do not consider the therapy patients to be blinded. NECTAR-HF
is therefore a single-blind study, with only the clinicians involved
in data collection, such as echocardiography, exercise testing, and
clinical assessment, being blinded to treatment assignment.
Long-term follow up
Switching all patients to the ON mode at the end of the 6 month
randomized therapy period exposes the study to the confounding
ethical dilemma of implementing an unproven therapy to control
patients before the study is completed. However, because vagal
stimulation has a well-established safety profile in the epilepsy
population with more than 100 000 implants world-wide, it was
decided that crossing over the control patients to the ‘ON’ mode
carries an acceptable risk.
Additional VNS Studies for Heart Failure
INcrease Of VAgal TonE (INOVATE-HF)23 is a pivotal randomized
trial, sponsored by BioControl Medical (Yehud, Israel), examining
chronic vagal stimulation, by means of the same device used in the
pilot study,6 in HF patients. The patients will be randomized in a 3:2
ratio to receive active treatment after device implant and optimized
medical treatment of heart failure (without device implant). The
trial has as a primary efficacy endpoint the combination of all-cause
mortality and heart failure hospitalisation and intends to enrol 650
patients.
There are potentially important differences between the Boston
Scientific VNS system to be tested in NECTAR-HF and the Car-
dioFit device used in the INOVATE-HF trial. First, the CardioFit
system intracardiac lead allows the vagus nerve to be stimulated
at a certain phase of the cardiac cycle, based upon sensing the R
wave whereas the NECTAR-HF will not incorporate heart rate
sensing for therapy initiation or timing of the vagus nerve stim-
ulation to the cardiac cycle and will therefore evaluate whether
this approach, which avoids the need for an intracardiac lead, will











































































































.. different. The CardioFit stimulation lead is an asymmetric bipo-
lar multicontact cuff electrode specifically designed for cathodic
induction of action potentials, while simultaneously applying asym-
metrical anodal blocks expected to lead to preferential, but not
exclusive, activation of vagal efferent fibres.24 The two electrodes
exhibit grossly similar thresholds of activation of A and B fibres;24,25
however, nerve stimulation in the INOVATE-HF study will likely be
performed at higher amplitudes (but lower frequencies). Evaluation
of the results of the studies may increase our understanding of the
mechanisms linking vagus nerve stimulation to clinical benefit.
Finally, a single-arm open label study (ANTEM-HF)26 is currently
ongoing, assessing the tolerability and the effects of left sided and
right sided vagus nerve stimulation.
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